Fingerprint
Dive into the research topics of 'Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically